Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 5

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations

Authors Kesayan T, Shaw J, Jones T, Staffetti J, Zesiewicz T

Received 13 March 2015

Accepted for publication 7 May 2015

Published 3 July 2015 Volume 2015:5 Pages 63—72

DOI https://doi.org/10.2147/DNND.S37268

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Thomas Müller


Tigran Kesayan,1 Jessica D Shaw,1 Tracy M Jones,1 Joseph S Staffetti,1 Theresa A Zesiewicz1,2

1Department of Neurology, Morsani College of Medicine, University of South Florida, 2Department of Neurology, James A Haley VA Hospital, Tampa, FL, USA

Abstract: Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson’s disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson’s disease and RLS.

Keywords: rotigotine, dopamine agonist, Parkinson’s disease, restless legs syndrome

Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]